BOSTON, LONDON & TOKYO--(EON: Enhanced Online News)--Evaluate Ltd. today announced the launch of a strategic sales analytics solution that provides commercial teams and the investment community with a comprehensive view of life sciences product sales by country. Evaluate’s Product Sales Analysis by Country solution brings together IMS Health’s market-leading pharmaceutical sales information with Evaluate’s expert analyses of company-reported financials – providing analytics and insights that help clients to better assess commercial opportunities and company performance. Fully integrated with the EvaluatePharma® service, users can quickly analyze and quantify markets, the competition, therapy areas and indications by country.
“We are very excited to extend our analytics and insights to deliver greater client value”
“The combination of EvaluatePharma’s advanced functionality and publicly reported product sales with IMS Health’s robust, granular sales audits presents an accurate and complete picture of country-level sales performance, enabling clients to make informed decisions about market assessment, business transactions, licensing and other growth opportunities,” said Anthony Raeside, Head of Research, Evaluate Ltd.
Key features of the service include:
- Insights into the global, regional and local commercial product landscape in 70 countries
- Timely, accurate information to assess target candidates for in-license, out-license or acquisition opportunities
- Sophisticated analysis and reporting functionality
“We are very excited to extend our analytics and insights to deliver greater client value,” said Neil Jamieson, Head of Business Development, Evaluate Ltd. “Our new service enables stakeholders to save time and focus their energy on strategy and decision-making using the industry’s most timely and trusted data.”
For more information on Evaluate’s Product Sales Analysis by Country service and to contact Evaluate, please visit: http://www.evaluategroup.com/country.
About Evaluate Ltd.
Evaluate is the trusted source for life science market intelligence and analysis with exclusive consensus forecasts to 2018. We support life science and healthcare companies, financial institutions, consultancies and service providers in their strategic decision-making. Our services include EvaluatePharma, EvaluateClinicalTrials and EvaluateMedTech. Our global team of dedicated healthcare analysts employs rigorous methodologies to deliver strategic commercial analysis. We make our services valuable by combining superior quality content, user-friendly reporting tools and outstanding customer service to solve client problems. Our award-winning editorial team, EP Vantage, leverages our market intelligence and analysis to cut through the noise, giving you daily opinion and insights. The Evaluate services enable the life science community to make sound business decisions about value and opportunity. For more information please visit www.evaluategroup.com. On Twitter: @evaluatepharma, @evaluatemedtech, @epclinicaltrial, @epvantage.